Avella Newsroom

The following article was written by Avella's EVP of Clinical & Quality Assurance, Eric Sredzinski, and published in Specialty Pharmacy Times.

Oncology is already among the top therapeutic classes in specialty pharmacy.¹ Experts say that drugs to fight cancer will continue to dominate the next wave of FDA approvals and enter the market at a rapid pace. Yet specifically how these medications are delivered to patients is also expected to evolve over time. This is especially true as manufacturers look to partner with specialty pharmacies that possess highly specific expertise in supporting patients with cancer and their complex treatment regimens.

The specialty pharmacy will give patients access to this important new FDA-approved combination therapy for patients with advanced BRAF melanoma.

Phoenix, AZ -- Avella has announced that it will distribute BRAFTOVI™ (encorafenib) and MEKTOVI^® (binimetinib), a combination therapy recently FDA approved for patients for the treatment of patients with unresectable or metastatic melanoma with a BRAF^V600E or BRAF^V600K mutation, as detected by an FDA-approved test. 

Phoenix, AZ – The Arizona Chapter of The Leukemia & Lymphoma Society (LLS) announced today that Avella Specialty Pharmacy Executive Vice President Hamilton Baiden will serve as the Corporate Walk Chair of the 2018 Greater Phoenix Light The Night.

The specialty pharmacy will provide access to this FDA-approved, second-generation treatment for mantle cell lymphoma

Avella Specialty Pharmacy has issued its Outlook on Oncology report, a fact-based analysis that depicts the current state of the oncology industry and explores the trends, opportunities and new developments affecting cancer care delivery. The new white paper is available for download at avella.com/outlook-oncology

The data-rich report details how many of the changes taking place in the healthcare industry as a whole are specifically impacting the oncology space. One example cited is the real-time information exchange happening between healthcare stakeholders, which is enabling greater coordination of care for oncology patients. In a similar manner, new oncology-focused Accountable Care Organizations (ACOs) are fostering greater collaboration among payers, providers and pharmacies.

New therapy gives oncologists a powerful treatment option for patients with ovarian cancer

Avella has announced that it has been selected by Clovis Oncology to distribute RUBRACA^TM, an oral therapy for ovarian cancer. The drug was recently approved by the FDA for patients with advanced ovarian cancer who have previously received two types of chemotherapy agents.